These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21350875)

  • 21. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.
    Riccardi A; Brugnatelli S; Danova M; Giordano M; Pugliese P; Luchena G; Grasso D; Trotti G; Bertè R; Pansini G; Tinelli C
    Tumori; 2006; 92(1):6-12. PubMed ID: 16683377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer.
    Chan A; Willsher PC; Hastrich DJ; Anderson J; Barham T; Latham B; Redfern A; VAN DER Schaaf A; Thomson J; Joseph D; Ingram D
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):62-70. PubMed ID: 22369445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
    Firouzabadi D; Dehghanian A; Rezvani A; Mahmoudi L; Talei A
    BMC Cancer; 2021 Jan; 21(1):47. PubMed ID: 33430808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
    Martín M; Ruiz A; Muñoz M; Balil A; García-Mata J; Calvo L; Carrasco E; Mahillo E; Casado A; García-Saenz JA; Escudero MJ; Guillem V; Jara C; Ribelles N; Salas F; Soto C; Morales-Vasquez F; Rodríguez CA; Adrover E; Mel JR;
    Lancet Oncol; 2007 Mar; 8(3):219-25. PubMed ID: 17329192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
    Alvarado-Miranda A; Arrieta O; Gamboa-Vignolle C; Saavedra-Perez D; Morales-Barrera R; Bargallo-Rocha E; Zinser-Sierra J; Perez-Sanchez V; Ramirez-Ugalde T; Lara-Medina F
    Radiat Oncol; 2009 Jul; 4():24. PubMed ID: 19591689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
    Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
    Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
    Gómez-Bernal A; Cruz JJ; García-Palomo A; Arizcun A; Pujol E; Diz P; Martín G; Fonseca E; Sánchez P; Rodríguez C; del Barco E; López Y
    Am J Clin Oncol; 2003 Apr; 26(2):127-31. PubMed ID: 12714881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
    Bear HD; Tang G; Rastogi P; Geyer CE; Robidoux A; Atkins JN; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    N Engl J Med; 2012 Jan; 366(4):310-20. PubMed ID: 22276821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of vinorelbine, epirubicin, and cyclophosphamide as neoadjuvant chemotherapy for locally advanced breast cancer: phase II study.
    Braud AC; Levy E; Feuilhade F; Otmezguine Y; Calitchi E; Kirova Y; Le Bourgeois JP
    Am J Clin Oncol; 2002 Jun; 25(3):303-7. PubMed ID: 12040294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
    Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
    Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
    Heinemann V
    Oncology; 2003; 64(3):191-206. PubMed ID: 12697958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
    Gioulbasanis I; Saridaki Z; Kalykaki A; Vamvakas L; Kalbakis K; Ignatiadis M; Amarantidis K; Kakolyris S; Georgoulias V; Mavroudis D
    Anticancer Res; 2008; 28(5B):3019-25. PubMed ID: 19031950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
    Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
    Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.